No Result
View All Result
SUBMIT YOUR ARTICLES
  • Login
Thursday, October 2, 2025
TheAdviserMagazine.com
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
No Result
View All Result
TheAdviserMagazine.com
No Result
View All Result
Home Market Research Business

Why Is Biohaven Stock Falling On Thursday?

by TheAdviserMagazine
5 months ago
in Business
Reading Time: 3 mins read
A A
Why Is Biohaven Stock Falling On Thursday?
Share on FacebookShare on TwitterShare on LInkedIn


Biohaven Ltd. (NYSE:BHVN) shares plunged on Thursday after the Food and Drug Administration (FDA) unexpectedly delayed the review date for its rare-disease drug troriluzole.

The Division of Neurology 1 within FDA’s Office of Neuroscience informed Biohaven that they are extending the PDUFA date for the troriluzole new drug application (NDA) for spinocerebellar ataxia (SCA) by three months to provide time for a full review of Biohaven’s recent submissions related to information requests from the FDA.

If approved, troriluzole would be the first and only FDA-approved treatment for SCA. Spinocerebellar ataxia is a group of dominantly inherited neurodegenerative disorders characterized by progressive loss of voluntary motor control and atrophy of the cerebellum and brainstem. SCA affects approximately 15,000 people in the United States and 24,000 in Europe and the United Kingdom.

Also Read: Strong Immunoglobulin Reduction Data Positions Biohaven’s BHV-1300 As Potential Autoimmune Therapy

Patients experience significant morbidity, including impaired gait leading to falls, loss of ambulation and progression to a wheelchair, inability to communicate due to speech impairment, difficulty swallowing, and premature death.

The Division also informed Biohaven that it is currently planning to hold an advisory committee meeting to discuss the application, but no date has been scheduled.

The FDA did not raise any new concerns in the letter. The FDA’s decision regarding the NDA is expected in the fourth quarter of 2025, compared to the third quarter of 2025, which was expected earlier.

Vlad Coric, Chairman and Chief Executive Officer of Biohaven, stated, “The clinical data presented in the NDA show a highly favorable benefit-risk profile with troriluzole, a once-daily oral pill, slowing disease progression by 50-70%, as measured by the f-SARA scale, and reducing the risk of falls.”

The company recently completed the FDA mid-cycle review meeting and regulatory inspections of Biohaven and key clinical research sites for troriluzole for SCA. The mid-cycle review concluded that there were no previously unidentified major safety concerns, and it does not appear a Risk Evaluation and Mitigation Strategy (REMS) is needed.

In April, the company announced an up to $600 million non-dilutive capital agreement with Oberland Capital Management LLC. The agreement, with $250 million in gross proceeds received on closing on April 30, 2025, is expected to support commercial launch planning in SCA, clinical development activities, and ongoing business operations.

Story Continues

Cash, cash equivalents, marketable securities and restricted cash as of April 30, 2025 totaled approximately $518 million.

Analysts at William Blair called the delay surprising, especially given the proximity to the completed mid-cycle review. Biohaven shares are trading down in response to the PDUFA extension and an FDA regulatory landscape with increasing uncertainty given restructuring efforts, as per William Blair.

“We understand the uncertainty here and the perceived increase in regulatory uncertainty, but we remain optimistic that the FDA will show more regulatory flexibility than the EMA given the rare-disease nature of SCA, lack of treatment options for the disease, and troriluzole’s risk/benefit compared to propensity-matched natural history data,” William Blair analysts said.

William Blair reiterates the Outperform rating given the conviction in the likelihood of approval.

Price Action: BHVN stock is down 14.3% at $16.85 at the last check on Thursday.

Read Next:

Image by Tada Images via Shutterstock

Date

Firm

Action

From

To

Mar 2022

Mizuho

Maintains

Buy

Jan 2022

Morgan Stanley

Maintains

Equal-Weight

Nov 2021

Mizuho

Maintains

Buy

View More Analyst Ratings for BHVN

View the Latest Analyst Ratings

UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.

Get the latest stock analysis from Benzinga?

This article Why Is Biohaven Stock Falling On Thursday? originally appeared on Benzinga.com

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.



Source link

Tags: BiohavenfallingstockThursday
ShareTweetShare
Previous Post

Diversification through luxury watches? Advisors have thoughts

Next Post

IAI eyes takeover of Spacecom

Related Posts

edit post
Biden’s Florida legacy: An economic boom, a magnet for immigrants and a solidly conservative red state

Biden’s Florida legacy: An economic boom, a magnet for immigrants and a solidly conservative red state

by TheAdviserMagazine
October 2, 2025
0

After Paola Freites was allowed into the U.S. in 2024, she and her husband settled in Florida, drawn by warm...

edit post
Market trading guide: Buy Hindustan Zinc, Fortis Health and 2 more stocks for up to 9% gains – Stock Ideas

Market trading guide: Buy Hindustan Zinc, Fortis Health and 2 more stocks for up to 9% gains – Stock Ideas

by TheAdviserMagazine
October 2, 2025
0

India’s benchmark indices, the Nifty and Sensex, ended their eight-day losing streak, led by private banks, auto, and IT stocks....

edit post
PepsiCo’s new challenge: Making its chips and sodas colorful without artificial dyes

PepsiCo’s new challenge: Making its chips and sodas colorful without artificial dyes

by TheAdviserMagazine
October 2, 2025
0

Pepsi has a new challenge: keeping products like Gatorade and Cheetos vivid and colorful without the artificial dyes that U.S....

edit post
What CEOs are saying about the government shutdown

What CEOs are saying about the government shutdown

by TheAdviserMagazine
October 2, 2025
0

Good morning. I was talking to a CEO over the phone yesterday about the potential business impact of a government...

edit post
Sign of the times as Swiss buy euros, not dollars

Sign of the times as Swiss buy euros, not dollars

by TheAdviserMagazine
October 2, 2025
0

The Swiss National Bank may be a special case, but if you were looking for a switch in the behavior...

edit post
Lyft CEO on the time Bill Gates told him he was making ‘the stupidest decision I’ve ever heard anyone made’

Lyft CEO on the time Bill Gates told him he was making ‘the stupidest decision I’ve ever heard anyone made’

by TheAdviserMagazine
October 1, 2025
0

Before David Risher was tasked with scripting a “comeback story” for ride-sharing company Lyft, he made a career move so...

Next Post
edit post
IAI eyes takeover of Spacecom

IAI eyes takeover of Spacecom

edit post
There Are Only Two Major Opportunities For OMS Vendors To Win New Deals Right Now

There Are Only Two Major Opportunities For OMS Vendors To Win New Deals Right Now

  • Trending
  • Comments
  • Latest
edit post
What Happens If a Spouse Dies Without a Will in North Carolina?

What Happens If a Spouse Dies Without a Will in North Carolina?

September 14, 2025
edit post
California May Reimplement Mask Mandates

California May Reimplement Mask Mandates

September 5, 2025
edit post
Does a Will Need to Be Notarized in North Carolina?

Does a Will Need to Be Notarized in North Carolina?

September 8, 2025
edit post
Who Needs a Trust Instead of a Will in North Carolina?

Who Needs a Trust Instead of a Will in North Carolina?

September 1, 2025
edit post
DACA recipients no longer eligible for Marketplace health insurance and subsidies

DACA recipients no longer eligible for Marketplace health insurance and subsidies

September 11, 2025
edit post
‘Quiet luxury’ is coming for the housing market, The Corcoran Group CEO says. It’s not just the Hamptons, Aspen, and Miami anymore

‘Quiet luxury’ is coming for the housing market, The Corcoran Group CEO says. It’s not just the Hamptons, Aspen, and Miami anymore

September 9, 2025
edit post
Market trading guide: Buy Hindustan Zinc, Fortis Health and 2 more stocks for up to 9% gains – Stock Ideas

Market trading guide: Buy Hindustan Zinc, Fortis Health and 2 more stocks for up to 9% gains – Stock Ideas

0
edit post
Biden’s Florida legacy: An economic boom, a magnet for immigrants and a solidly conservative red state

Biden’s Florida legacy: An economic boom, a magnet for immigrants and a solidly conservative red state

0
edit post
Warren Buffett Berkshire Occidental Oxychem

Warren Buffett Berkshire Occidental Oxychem

0
edit post
Shekel gains sharply amid optimism on Trump plan

Shekel gains sharply amid optimism on Trump plan

0
edit post
James Comey Is Not an Innocent Victim of the Lawfare He Helped to Create

James Comey Is Not an Innocent Victim of the Lawfare He Helped to Create

0
edit post
XRP Falls 2.3% As Ripple CTO David Schwartz Exits

XRP Falls 2.3% As Ripple CTO David Schwartz Exits

0
edit post
Biden’s Florida legacy: An economic boom, a magnet for immigrants and a solidly conservative red state

Biden’s Florida legacy: An economic boom, a magnet for immigrants and a solidly conservative red state

October 2, 2025
edit post
James Comey Is Not an Innocent Victim of the Lawfare He Helped to Create

James Comey Is Not an Innocent Victim of the Lawfare He Helped to Create

October 2, 2025
edit post
Warren Buffett Berkshire Occidental Oxychem

Warren Buffett Berkshire Occidental Oxychem

October 2, 2025
edit post
Market trading guide: Buy Hindustan Zinc, Fortis Health and 2 more stocks for up to 9% gains – Stock Ideas

Market trading guide: Buy Hindustan Zinc, Fortis Health and 2 more stocks for up to 9% gains – Stock Ideas

October 2, 2025
edit post
PepsiCo’s new challenge: Making its chips and sodas colorful without artificial dyes

PepsiCo’s new challenge: Making its chips and sodas colorful without artificial dyes

October 2, 2025
edit post
What CEOs are saying about the government shutdown

What CEOs are saying about the government shutdown

October 2, 2025
The Adviser Magazine

The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.

CATEGORIES

  • 401k Plans
  • Business
  • College
  • Cryptocurrency
  • Economy
  • Estate Plans
  • Financial Planning
  • Investing
  • IRS & Taxes
  • Legal
  • Market Analysis
  • Markets
  • Medicare
  • Money
  • Personal Finance
  • Social Security
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • Biden’s Florida legacy: An economic boom, a magnet for immigrants and a solidly conservative red state
  • James Comey Is Not an Innocent Victim of the Lawfare He Helped to Create
  • Warren Buffett Berkshire Occidental Oxychem
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • Contact us
  • About Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.